

BEP RUN 2 (2021) ROADSHOW

Prof Malini Olivo (co ED-In-Charge)

Dr Su Yi (co ED-In-Charge)

Health & MedTech Horizontal Technology
Programme Office (HMT HTPO)

July 2021

ARES PUBLIC

Housekeeping rules



Record

This session will be recorded.



Q&A

If you have questions at any point, type them in the Q&A box.



Upvote

You can upvote questions in the Q&A box.



Chat

If you wish to pose a question verbally during Q&A segment, type "+1" in Chat box.






AGENDA

TIME	ITEM	SPEAKER(S)
5min	Opening address	Dr Su Yi <i>Co ED-In-Charge, HMT HTPO</i> <i>DED, IHPC</i> <i>Director, Strategic Planning and Development</i>
15min	Objective and overview of the BEP	Dr Maple Ye <i>Lead, HMT HTPO</i> <i>DD, BMRC MedTech</i>
10min	Overview of SB Workshop	Dr Lee Phin Peng <i>Deputy Programme Director, Singapore Biodesign (SB)</i>
30min	Q&A	Moderator



BIOMEDICAL ENGINEERING PROGRAMME (BEP)

a competitive, multidisciplinary funding initiative aimed at supporting clinically-driven MedTech innovations with promising commercialization potential





BIOMEDICAL ENGINEERING PROGRAMME (BEP)

a competitive, multidisciplinary funding initiative aimed at supporting clinically-driven MedTech innovations with promising commercialization potential

- **Suitable for projects at TRL 2 – 4 (i.e. Proof-of-Concept)**
 - TRL 2: Experimental prototype (can be in parts to test concept/idea)
 - TRL 3: Feasibility prototype (further assembled and demonstrated feasibility of key features)
 - TRL 4: Working prototype (looks like final product with integrated functions/features)
- **Not restricted to any specific clinical or technical domains**
- **Expected deliverables:**
 - Technology deliverables like a lab prototypes to illustrate the feasibility of the tech solution in addressing the clinical unmet need
 - Clinical deliverables such as a clinical need validation, clinical feedback collection, pilot trial etc.



SCOPE OF MEDTECH

What is Medical Technology?

Medical technologies are products, services or solutions used to save and improve people's lives.

This can include the following:

- (i) Devices; defined as products which are used to **diagnose, alleviate or treat a medical condition**, e.g. X-ray machines, contact lenses, prosthetic knee implants
measure or monitor functions of the body, e.g. blood pressure or blood sugar monitoring machines
- (ii) In vitro diagnostics (IVDs); defined as **reagents, instruments, and systems** intended for use in the diagnosis of disease or other conditions.
- (iii) Software as a Medical Device (SaMD); defined as **software intended to be used for one or more medical purposes that perform these purposes without being part of a hardware medical device**, e.g. telehealth, image analysis software, personalized medicine etc
- (iv) Digital health products; which includes categories such as mobile health (mHealth), health information technology (IT), wearable devices, telehealth and telemedicine, and personalized medicine
- (v) Any combination of the above categories

This does not include (non-exhaustive):

- Pharmaceuticals such as small molecules, biologics, or otherwise other compounds which achieve its primary intended purposes through **chemical action** within or on the body of man or other animals and which is not dependent upon being **metabolized** for the achievement of its primary intended purposes
- Health and wellness products (without medical claims)
- Electronic health records system, or software to improve productivity of healthcare operations

MEDTECH CAN BE USED FOR





Categories of Medical Technology Products

Segments

- IVD
- Cardiology
- Diagnostic Imaging
- Orthopedics
- Ophthalmology
- General & Plastic Surgery
- Endoscopy
- Drug Delivery
- Dental
- Wound Management
- Diabetic Care
- Nephrology
- General Hospital and Healthcare Supply
- Neurology
- ENT
- Others (Wound care management, Healthcare IT, etc.)

MedTech: Devices & Diagnostics

Capital Equipment



Software/SaMD



Consumables/Supplies



Implantables



Reagents & Kits



Drug Delivery





BEP RUN 2 CALL FOR PROPOSAL DETAILS

Call opens: 21st June 2021

Apply via iGrants: <https://app.a-star.edu.sg/igrants/>.

Application guidelines provided in Info Deck

Deadline for LOI submission:

30 July 2021

Project Duration: 12-18 Months

Funding Quantum: up to S\$500k/project¹

Funding can support EOM², EQPT, OOE & Travel.


Apply via iGrants: <https://app.a-star.edu.sg/igrants/>.

See section on “Application Guidelines”.

¹Inclusive of overheads for non-A*STAR institutes

²PI EOM is not supported. At least 2/3 of FTE must be new staff/existing staff not in any funding in related areas

IMPORTANT DATES





ELIGIBILITY CRITERIA

Teams must comprise at least:

- **1 Clinical PI**; with a primary appointment[#] in a public healthcare institution or academic medical school in Singapore and be salaried by the institution, and
- **1 Technical PI**; with >50% commitment in an A*STAR entity.

Teams may choose to include multiple performers as **Co-Investigators** (Co-Is) on a single project, including performers from Institutes of Higher Learning (IHLs) and other public-funded research entities, but this is not mandatory.

All proposals must include both technical and clinical deliverables to demonstrate significant contributions from both the technical and clinical sides of each team.

[#]Refers to medical practitioners registered in Singapore, including physicians, nurses, and Allied Health professionals, who have access to patients and can demonstrate that he/she can achieve the relevant clinical deliverables for the project.



REVIEW PROCESS & ASSESSMENT CRITERIA

Under the BEP, submissions will be reviewed in 2 stages, as described below.

1. LOI Review & Shortlist

From the LOI submissions received, **up to 12 teams** are expected to be shortlisted. LOIs will be reviewed by up to 3 LOI reviewers representing the technical, clinical and business domains.

2. Final Review (*for shortlisted applicants only*)

Teams are expected to present at the Final Review to a panel of reviewers from various backgrounds such as academic, clinical and industry. Final decision on funding will be decided after the Final Review.

Assessment Criteria:

1. Technical feasibility
2. Clinical impact and feasibility for clinical adoption
3. Target market size and commercialisation potential



Key elements for successful BEP applications

1. Technical feasibility

- Performance (having preliminary data helps!)
- Scalability/manufacturability

2. Clinical adoptability

- Integrability with existing clinical infrastructure and workflow
- Cost/benefit ratio

3. Commercialization potential

- Market size
- IP freedom to operate
- Competitive analysis

4. Team dynamics

- Engaging clinical partner(s)
- Commitment to bringing technology to market



APPLICATION GUIDELINES

Letter of Intent (LOI) shall be submitted electronically through iGrants.

**E-mail applications will not be accepted.
Incomplete submissions will be disqualified.**

Applicants are advised to submit their applications early in the event of technical errors with the iGrants website.

If you encounter difficulties with account creation on iGrants, please write to A-STAR_OGA@hq.a-star.edu.sg for help.

The following slides outline steps for “Using iGrants” and “LOI Submission”.



TIMELINE OF EVENTS (INDICATIVE)

FOR ALL APPLICANTS & INTERESTED PARTIES

Call for proposal	21 June 2021
Virtual Roadshow for BEP; 2 sessions available	5 & 19 July 2021
LOI submission deadline	30 July 2021
Notification of LOI shortlisting outcome	Early September 2021

FOR SHORTLISTED APPLICANTS ONLY

Singapore Biodesign 2-day Workshop for BEP	20 & 21 September 2021
Full proposal submission deadline	6 October 2021
Presentation at Final Review	Early November 2021

FOR SUCCESSFUL APPLICANTS

In-principle approval	End November 2021
Letter of Allocation	End December 2021



SINGAPORE BIODESIGN WORKSHOP FOR BEP

When is the workshop?

Tentatively 20 & 21 September 2021; 9 AM – 6 PM

Who should attend?

Only shortlisted teams after the LOI evaluation will be required to attend. Teams will be informed by early Sep if they have been shortlisted. **Up to 3 people per team may attend.** It is **compulsory for both the Clinical PI and Technical PI** to attend the 2-day workshop.

Why is this important?

The robust Biodesign methodology has consistently demonstrated an outstanding track record in the ability to **de-risk projects at the planning stages**, with a multi-disciplinary and systematic approach for the identification and validation of important unmet healthcare needs, the development of novel technologies to address them, and the subsequent development of business and commercialization plans to bring them into patient care.

Through this workshop, project teams can benefit from high-touch training support to inculcate a Biodesign approach in their projects, and gain a high-level understanding of the various processes and considerations in their journey towards market approval. This will help teams in drafting a full proposal that can address the evaluation criteria for the BEP.



CONTACT INFORMATION

For general queries, please refer to the “**BEP Run 2 FAQs v2.3**”.

If you require further clarification, you may reach us at HMT@hq.a-star.edu.sg. Please allow up to 3 working days for us to provide a response.

For queries related to iGrants, please reach out to A-STAR_OGA@hq.a-star.edu.sg.

HMT HTPO Seed Fund Secretariat

Nigel Tan

Douglas Goh

Suhaila Binte Mohamad Zan

Diana Wan



CREATING GROWTH, ENHANCING LIVES



THANK YOU

www.a-star.edu.sg